{"organizations": [], "uuid": "1c02bf92f3a263d37e5aebbff6944b3fd80534b4", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180409.html", "section_title": "Archive News &amp; Video for Monday, 09 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-takara-bio-signs-agreement-for-co/brief-takara-bio-signs-agreement-for-co-development-and-sales-rights-in-japan-to-ny-eso-1-sitcrtm-and-cd19-car-gene-therapies-idUSL3N1RM1VK", "country": "US", "domain_rank": 408, "title": "BRIEF-Takara Bio signs agreement for co-development and sales rights in Japan to NY-ESO-1 siTCRTM and CD19 CAR gene therapies", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.461, "site_type": "news", "published": "2018-04-09T14:39:00.000+03:00", "replies_count": 0, "uuid": "1c02bf92f3a263d37e5aebbff6944b3fd80534b4"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-takara-bio-signs-agreement-for-co/brief-takara-bio-signs-agreement-for-co-development-and-sales-rights-in-japan-to-ny-eso-1-sitcrtm-and-cd19-car-gene-therapies-idUSL3N1RM1VK", "ord_in_thread": 0, "title": "BRIEF-Takara Bio signs agreement for co-development and sales rights in Japan to NY-ESO-1 siTCRTM and CD19 CAR gene therapies", "locations": [], "entities": {"persons": [{"name": "otsuka pharmaceutical", "sentiment": "negative"}], "locations": [{"name": "japan", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "takara bio inc", "sentiment": "negative"}, {"name": "takara", "sentiment": "none"}, {"name": "beijing headline news", "sentiment": "none"}, {"name": "ltd", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 9(Reuters) - Takara Bio Inc\n* Says it has entered into an agreement with Otsuka Pharmaceutical Co., Ltd for co-development and exclusive sales rights in Japan for Takaraâ€™s NY-ESO-1 siTCRTM (TBI-1301, TBI-1301-A) and CD19 CAR (TBI-1501) gene therapies\nSource text in Japanese: goo.gl/YzGkkU\nFurther company coverage: (Beijing Headline News)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/", "https://goo.gl/YzGkkU"], "published": "2018-04-09T14:39:00.000+03:00", "crawled": "2018-04-10T13:04:30.029+03:00", "highlightTitle": ""}